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Abstract
Background: Smith-Magenis syndrome (SMS) is a developmental disability/multiple congenital anomaly disorder
resulting from haploinsufficiency of RAI1. It is characterized by distinctive facial features, brachydactyly, sleep
disturbances, and stereotypic behaviors.
Methods: We investigated a cohort of 15 individuals with a clinical suspicion of SMS who showed neither deletion
in the SMS critical region nor damaging variants in RAI1 using whole exome sequencing. A combination of network
analysis (co-expression and biomedical text mining), transcriptomics, and circularized chromatin conformation
capture (4C-seq) was applied to verify whether modified genes are part of the same disease network as
known SMS-causing genes.
Results: Potentially deleterious variants were identified in nine of these individuals using whole-exome sequencing.
Eight of these changes affect KMT2D, ZEB2, MAP2K2, GLDC, CASK, MECP2, KDM5C, and POGZ, known to be associated
with Kabuki syndrome 1, Mowat-Wilson syndrome, cardiofaciocutaneous syndrome, glycine encephalopathy, mental
retardation and microcephaly with pontine and cerebellar hypoplasia, X-linked mental retardation 13, X-linked mental
retardation Claes-Jensen type, and White-Sutton syndrome, respectively. The ninth individual carries a de novo variant
in JAKMIP1, a regulator of neuronal translation that was recently found deleted in a patient with autism spectrum
disorder. Analyses of co-expression and biomedical text mining suggest that these pathologies and SMS are part of the
same disease network. Further support for this hypothesis was obtained from transcriptome profiling that showed that
the expression levels of both Zeb2 and Map2k2 are perturbed in Rai1–/– mice. As an orthogonal approach to potentially
contributory disease gene variants, we used chromatin conformation capture to reveal chromatin contacts between
RAI1 and the loci flanking ZEB2 and GLDC, as well as between RAI1 and human orthologs of the genes that show
perturbed expression in our Rai1–/– mouse model.
Conclusions: These holistic studies of RAI1 and its interactions allow insights into SMS and other disorders associated
with intellectual disability and behavioral abnormalities. Our findings support a pan-genomic approach to the
molecular diagnosis of a distinctive disorder.
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Background
Smith-Magenis syndrome (SMS; MIM #182290) is a rare
genomic disorder with a prevalence of 1 in 15,000. It is as-
sociated with specific craniofacial dysmorphology,
developmental delay (DD), moderate to profound intellec-
tual disability (ID), and self-injurious and stereotypic be-
haviors [1, 2]. SMS individuals show sleep disturbance
with frequent daytime napping and night-time awaken-
ings. They display restricted interest, obsessive thinking,
and social responsiveness scale scores consistent with aut-
ism spectrum disorder (ASD) [3]. They repetitively mouth
objects, rock, spin, or twirl their body, and grind their
teeth [4]. This distinctive profile is complemented by spe-
cific lick and flip and self-hug behaviors, as well as attach-
ment to people [5–7]. Challenging behaviors such as self-
injuries, physical aggression, and destructive behavior are
significantly more prevalent in SMS than in ID with mixed
etiologies [8]. Self-injuries are present in 70–97 % of indi-
viduals and include polyembolokoilamania (insertion of
foreign objects into bodily orifices) and onychotillomania
(pulling out finger and toe nails). Unusual behaviors can
comprise poking others’ eyes, forceful hugging, and
punching fists through walls and windows.
Whereas SMS is classically associated with a deletion
within cytogenetic G-band 17p11.2 that includes the
RAI1 gene (about 90 % of individuals) or a nucleotide
variant in that gene (about 5 %) [1, 9–12], some reports
suggested genetic heterogeneity as SMS-like individuals
were found to recurrently harbor deletions of the 2q37.3
or 2q23.1 cytobands encompassing HDAC4 and MBD5,
respectively [13–15]. Similarly, PITX3 was proposed to
be responsible for the SMS-like neurobehavioral abnor-
malities observed in an individual [16].
Here we use recent advances in genome sequencing
technologies to further assess the genetic heterogeneity
of SMS and the possible clinical overlap of this syn-
drome with other intellectual disability and cognitive
dysfunction disorders, as some of the seemingly charac-
teristic phenotypic features are non-discriminating
among ID syndromes. We also evaluate the pertinence
of network interactions and provide experimental data
in support of potential molecular diagnoses.
Methods
Enrollment
Each of the 149 patients was clinically assessed by
their respective physicians. Patients were diagnosed as
potentially affected by SMS through clinical assess-
ment. Briefly, all individuals presented intellectual dis-
ability and/or developmental delay, and the majority
(>75 %) also had sleep disturbances, stereotypies, or
other endophenotypes common to SMS (e.g. distinct-
ive facial features, tantrums, self-injurious behaviors,
onychotillomania). The clinical presentation of SMS is
heterogeneous; therefore, the indication of SMS by a
clinician can be either premature in the case of a
young infant or possibly a misdiagnosis in an individ-
ual with behavioral issues and ID.
Detailed SMS patients’ phenotypes
The detailed phenotype descriptions of 13 of the 15
patients without RAI1 genetic alteration are described in
Additional file 1: Supplementary text and Additional
file 2: Table S1. The remaining two individuals had
no clinical data available.
Array comparative genomic hybridization
Targeted chromosome 17p array comparative genomic
hybridization (aCGH) analyses were carried out on each
proband as previously reported [17]. Additional genome-
wide aCGH was conducted on each person using Baylor
Miraca Genetics Laboratory design version 10.1, an
Agilent 180 K oligo array. All array data were analyzed
as previously described [18].
Exome sequencing
To uncover genetic variants associated with the abnormal-
ities shown by the 15 patients without RAI1 genetic alter-
ation, we performed whole-exome sequencing of DNA
extracted from blood of the proband and both their parents
whenever possible (eight trios) at the Baylor College of
Medicine (BCM) Human Genome Sequencing Center
(HGSC) via the Baylor-Hopkins Center for Mendelian Gen-
etics. Exomes were captured and sequenced on an Illumina
HiSeq platform using previously described methods [19]. Se-
quence analysis was performed using the HGSC Mercury
analysis pipeline (https://www.hgsc.bcm.edu/software/mer-
cury) [20]. Variants were filtered based on inheritance pat-
terns including autosomal recessive, X-linked, and de novo/
autosomal dominant. Variants with MAF < 0.05 in control
cohorts (Atherosclerosis Risk in Communities (ARIC,
https://www2.cscc.unc.edu/aric/), 1000 Genomes project
(http://www.1000genomes.org/), the NHLBI Exome Sequen-
cing Project (http://evs.gs.washington.edu/EVS/), and our
internal BCM control database of > 5000 exomes generated
as a member of the Centers for Mendelian Genomics) [21]
and predicted to be deleterious by SIFT10 and/or PolyPhen
were prioritized [19]. Sanger sequencing confirmed puta-
tively causative variants and their familial segregation.
The sequencing variants identified in this manuscript
were deposited in ClinVar (https://www.ncbi.nlm.nih.-
gov/clinvar/).
Modeling
The primary sequence of each candidate protein was
loaded in Swiss-PdbViewer aligned onto suitable modeling
templates retrieved from SWISS-MODEL and superposed
in three-dimensional (3D) space using Swiss-PdbViewer
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[22, 23]. Each variant was modeled in the context of the
overall 3D structure to evaluate its potential impact with
respect to protein folding, as well as to position of known
disease-associated variants. We also assessed if missense
variants perturbing the protein function clustered in 3D
around key regions of the protein [24].
The ZEB2 Zinc finger residues 995–1078 were mod-
eled using the pdb entry 1mey as template [25].
MAP2K2 was modeled using both MAP2K2 (pdb entry
1s9i 3.2A resolution [26] and MAP2K1 (pdb entry 3eqi,
1.9A resolution) structures [27]. The GLDC residues
were aligned on the Synechocystis sp. glycine decarboxylase
model PCC 6803 (pdb entry 4LHD) [28]. To model the
CASK variants, two partial CASK crystal structures (pdb
entries 1kwa, chain A [29] and 1kgd, chain A (http://
www.ncbi.nlm.nih.gov/pubmed/11729206?dopt=Abstract))
covering residues 487–572 and 739–914, respectively, were
superposed on the crystal structure of PALS1/Crb (pdb
entry 4wsi [30]) that present 35 % identity with CASK.
Literature mining
Because literature resources do not use entity name in a
consistent way, we first checked each gene identifier by
using UniProtKB (http://www.uniprot.org) or HUGO Gene
Nomenclature Committee (HGNC) database (http://
www.genenames.org) in order to retrieve the recom-
mended/approved name, short name(s), alternative and syn-
onymous name(s) if any for each targeted gene, as well as
the name(s) of the encoded protein. These were used as
singleton and/or pairwise strings to extract information
from various literature resources: PubMed (http://
www.ncbi.nlm.nih.gov/pubmed), Google Scholar, iHOP
(http://www.ihop-net.org/UniPub/iHOP/), and EVEX
(http://evexdb.org/), to cite here the original source of refer-
ence for this project. The obtained results were curated and
the reported relationships were visualized using Cytoscape
(3.2.1; http://www.cytoscape.org/). The connectivity was
assessed using the Knet-function, which is based on the
adaptation of spatial statistics concepts to network analysis
proposed in [31]. The statistical significance of the obtained
Knet-function value was calculated with respect to a popula-
tion of permuted networks (n = 106) derived from the ori-
ginal prior knowledge network. It is worth noting here that
the connectivity is not only based on direct but also on in-
direct connections through shortest paths.
Identification of RAI1 interacting proteins
We identified ZBTB17/MIZ1 and BRD2 as likely inter-
actors for RAI1 with a yeast two-hybrid assay. The yeast
two-hybrid assays were performed in collaboration with
the company Proteinlinks. Briefly, two fragments of the
carboxyl-terminus of mouse Rai1 (a.a 1246–1841 and
a.a. 1246–1890) were cloned into pCWX200 as baits.
Around 10 million independent complementary DNA
(cDNA) library clones (10× library coverage) were
screened for protein–protein interactions with both
baits. We cultured the Y304 yeast strain on galactose se-
lective medium without leucine, histidine, trytophan,
and uracil. Positive clones were replicated onto the four
selective plates and examined with URA3 (or LEU2) and
LacZ reporters. From this analysis, we identified
ZBTB17/MIZ1, BRD2, and SOGA3 as reasonable candi-
dates (at least two clones, supported by both baits) for
RAI1 interaction candidates. These interactions were
further assessed using co-immunoprecipitation (co-IP)
analysis in HEK293 cells. Full-length Rai1 was cloned in
pCMV-3xFLAG vector while the three candidates were
cloned into pCMV-HA vectors to confirm the yeast two-
hybrid results. Lysate from the co-transfected HEK293
cells (RAI1 and one of the candidates) was purified with
EZview FLAG-M2 beads (Sigma) and analyzed with rat
anti-HA (Abcam) on western blot. The interaction
between RAI1 and ZBTB17/MIZ1 was confirmed by co-
IP, however BRD2 did not express well enough on west-
ern blot, and SOGA3 was too sticky to conduct co-IP
with, as it bound to the beads in the absence of FLAG-
RAI1 (Additional file 3: Figure S1).
Embryo collection and RNA extraction
Mice were housed in standard specific pathogen-free
conditions. All animal studies were conducted under
protocols approved by the Baylor Institutional Animal
Care and Use Committee and followed NIH guidelines.
Timed matings between Rai1 heterozygous females and
males in F2 generation in the C57BL/6 Tyrc-Brd and
129SvEv mixed genetic background were implemented
to generate Rai1–/– embryos. To harvest embryos, preg-
nant females were sacrificed by cervical dislocation and
the embryos were dissected from the uterus in ice-cold
phosphate buffered saline (PBS) solution. Similar sized
embryos at 10.5 days post conception (dpc) were col-
lected in 1.5 mL Eppendorf tubes, frozen immediately in
liquid nitrogen, and stored in –80 °C. Portions of the
yolk sac were saved for genotyping as described previ-
ously [32]. For RNA extraction, the whole embryos were
homogenized in Trizol and RNA was extracted accord-
ing to the manufacturer’s instructions (Invitrogen)
followed by purification on columns using an RNeasy
mini kit (Qiagen Sciences, Germantown, MD, USA).
The RNA integrity, concentration, and overall quality
were tested with an Agilent Bioanalyzer 2100 and a
NanoDrop ND-1000 spectrophotometer.
Microarray processing and analysis
A total of 5–10 μg of total RNA from each individual
embryo of three Rai1–/– at 10.5 dpc and three wild-type
controls were used to produce complementary RNA
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(cRNA) target microarray transcriptome analyses.
Embryos at 10.5 dpc were chosen because Rai1 func-
tions during this stage as indicated by its strong expres-
sion and embryonic lethality of Rai1–/– embryos from
7.5 to 18.5 dpc [32]. In addition, the size of the Rai1–/–
embryos at 10.5 dpc is comparable to that of their wild-
type littermates whereas the few surviving Rai1–/– mice
at birth are significantly smaller than the wild-type [32].
The integrity and quality of the extracted RNAs were
assessed on a 2100 Bioanalyzer (Agilent, Santa Clara,
CA, USA). The target was generated using a reverse
transcription reaction to produce cDNA (SuperScript
Choice System, Gibco), which was subsequently sub-
jected to in vitro transcription with biotinylated
cytidine-5′-triphosphate and uridine-5′-triphosphate
using ENZo BioArray High Yield RNA Transcript Label-
ing kit to produce biotinylated cRNA. The target was
then fragmented and hybridized to Affymetrix Mouse
Genome 430 2.0 Array GeneChips (Affymetrix, Santa
Clara, CA, USA) in duplicates using an Affymetrix Gen-
eChip Fluidics Station 400. The arrays were stained with
phycoerythrin-coupled avidin and scanned using a Gen-
eArray Scanner 3000. The resultant output was analyzed
using Affymetrix Microarray Suite software and exam-
ined for excessive background or evidence for RNA deg-
radation. The chips were assessed by scaling factor,
average background, percent of probe sets that are
present, number of probes present, and the 3′-end to
5′-end probe intensity ratio for housekeeping probe sets
(β-actin and GAPDH), as well as the number of probes
present for the “spiked in” probe sets (BioB, BioC, BioD,
and Crex). All the chips were of good quality, which is
further supported by the observations that they have
similar RNA degradation patterns and the chips were
well replicated within the same genotype group as
shown by scatter plot analyses. The criteria for genes
differentially expressed are that the log ratio of the nor-
malized expression values in the Rai1 deficient embryos
versus the controls is > 0.5 and the P value < 0.05, which
empirically gives a very low false detection rate (FDR).
The probe sets with very low expression values were
filtered out. We analyzed the chromosomal position of
all the regulated genes using the chromosomal coordi-
nates within recent genome assemblies of the mouse.
The array data were analyzed using the GC-RMA pro-
gram to estimate the expression measures from the
probe level data [33]. The program corrects the back-
ground, normalizes the raw perfect match data using the
quantile normalization method, and summarizes the probe
values to probe set values (expression values, one per probe
set per chip), in log2 scale. The fold change for each probe
is the log ratio of average expression value in the mutant
samples divided by that in the wild type controls. The fold
change is considered to be significant if P ≤ 0.05.
Reverse transcription polymerase chain reaction (RT-PCR)
validation
For RT-PCR validation of relevant expression targets,
1 μg of total RNA (intact by gel and measured by Nano-
Drop) was used for RT reactions using the Quanta
qScript cDNA synthesis kit. Three separate RT reactions
were performed using RNA from both a Rai1–/– embryo
and a wild-type control littermate. The RT reactions and
a non-RT reaction using wild-type RNA as well as a
water-only control were then run on a gel and all reac-
tions containing both RNA and RT had similar patterns
and intensity. A total of 1 μL of each RT reaction was
used for subsequent PCR reactions. Primers for PCR
were designed to transcript regions of Zeb2, Map2k2,
and Rai1 using the UCSC browser version of GRCm38/
mm10. The primers (from 5′ to 3′) are as follows:
Zeb2-8R: ATGTGAACTGTAGGACCCAGAATGA
Zeb2-7 F: CTTCAAGTACAAGCACCACCTGAA
Map2k2-2 F: TGAGAGGATCTCAGAGCTGGGT
Map2k2-3R: ACTCGTGCAGCACCTGCA
Rai1-4 F: ATGTATCCACACCTACCACTACCCAT
Rai1-5R: ACTTCAAAGTAAAATTCTCCTCAATGA
ACGT
4C-seq and 3C-PCR validation assays
Circularized chromosome conformation capture (4C)
libraries were prepared from lymphoblastoid cell lines
(LCLs) of two age-matched female control individuals.
Briefly, LCLs were grown at 37 °C. 5 × 107 exponentially
growing cells were harvested and crosslinked with 1 %
formaldehyde, lysed, and cut with DpnII, a 4-cutter re-
striction enzyme that allows higher resolution [34, 35].
After ligation and reversal of the crosslinks, the DNA
was purified to obtain the 3C library. This 3C library
was further digested with NlaIII and circularized to ob-
tain a 4C library. The inverse PCR primers to amplify
4C-seq (4C combined with multiplexed high-throughput
sequencing) templates were designed to contain Illumina
adaptor tails, sample barcodes, and viewpoint-specific
sequences. The selected viewpoint maps within the 5′
portion of the first intron of the RAI1 gene (700 bp from
the donor site of exon 1), a region enriched in DNaseI
hypersensitive and transcription factor binding sites [36].
It corresponds to the closest suitable DpnII fragment
relative to the transcriptional start sites of the targeted
gene. The sequence of the 4C-seq primers is reported in
Additional file 2: Table S2. We amplified at least 1.6 μg
of 4C template (using about 100 ng of 4C template per
inverse PCR reaction, for a total number of 16 PCRs).
We multiplexed the two 4C-seq templates in equimolar
ratios and analyzed them on a 100-bp single-end Illu-
mina HiSeq flow cell. The numbers of raw, excluded,
and mapped reads for each LCL sample are detailed in
Additional file 2: Table S3.
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To validate selected physical interactions and loop for-
mations between non-neighboring chromatin fragments,
5 × 107 exponentially growing cells were used in con-
junction with our 3C protocol as described [37]. We
tested primers positioned on the chromosome 17p11.2
sense strand 5′ to 3 for the cis-interactions and primers
designed at 9p24.1 compared to control 16p11.2 region
for the trans-interactions (Additional file 3: Figure S2
with primers tables). The presence of physical interac-
tions was determined by PCR amplimer production.
Control PCRs included no input (“water”) as well as
DNA from chromatin digested with DpnII but without
the subsequent religation step (“- Ligase”) (Additional
file 3: Figure S2).
4C-seq data analysis
4C-seq data were analyzed as previously described
[34, 35, 37] through the 4C-seq pipeline available at
http://htsstation.epfl.ch/) [38] and visualized with gFeat-
Browser (http://www.gfeatbrowser.com). Briefly, the
multiplexed samples were separated, undigested, and self-
ligated reads removed. Remaining reads were aligned and
translated to a virtual library of DpnII fragments. Read
counts were then normalized to the total number of reads
and replicates combined by averaging the resulting signal
densities (Additional file 3: Figures S3 and S4). The local
correlation between the profiles of the two samples per
viewpoint was calculated (Spearman correlation: 0.83).
The combined profiles were then smoothed with a win-
dow size of 29 fragments. The region directly surrounding
the viewpoint is usually highly enriched and can show
considerable experimental variation, thereby influencing
overall fragment count. To minimize these effects, the
viewpoint itself and the directly neighboring “undigested”
fragment were excluded during the procedure. In addition
to this filtering, we modeled the data to apply a profile
correction similar to the one described in [39] using a fit
with a slope -1 in a log-log scale [40]. Significantly inter-
acting regions were detected by applying a domainogram
analysis as described [41]. We selected BRICKS (Blocks of
Regulators In Chromosomal Kontext) with a p value
threshold < 0.01 for both “cis” and “trans” interactions,
and annotated the BRICKs overlapping genes as well as
the closest upstream and the closest downstream genes, in
a window of +/– 500 kb. The 4C libraries used to perform
the circular PCR with RAI1 viewpoint’s primers had been
previously tested in [35], with seven additional viewpoints’
primer pairs. The BRICKs genes GTDC1 and KDM4C
(and the flanking genes ZEB2 and GLDC) were not called
as significantly interacting regions for any of these view-
points (see [35]; Additional file 2: Tables S6–S12). The
raw sequencing files are available at GEO under accession
number GSE83420.
Enrichment analyses
Gene annotation was obtained through BioScript (http://
gdv.epfl.ch/bs). Protein interaction networks for BRICKs
genes were determined using STRING (Search Tool for
the Retrieval of Interacting Genes/Proteins) v9.1 (http://
string-db.org/) [42]. We exploited GO with Enrichr
(http://amp.pharm.mssm.edu/Enrichr/) to assess if the
chromatin-contacted genes were enriched in specific
pathways and genes associated with Mendelian diseases
and GIANT (http://giant.princeton.edu/) and Genema-
nia (http://www.genemania.org/) to test tissue-specific
functional interactions and produce association net-
works, respectively [43–46]. The significance of the con-
nectivity of the GIANT co-expression networks was
assessed as described for the literature-mining network
(see above). We used Enrichr Chromosome Location
tool and BRICKS count in different window sizes (5 Mb,
1 Mb, and 500 kb) to determine whether any cytogenetic
band other than 17p11.2 was enriched for BRICKS.
Other than 17p11.2, we identified significant enrich-
ments at cytobands 17p12, 17p13, and 2q22, where the
gene ZEB2 is located.
Hi-C data
Hi-C matrices from Rao et al. [47] were prepared by first
applying a KR normalization to the 5 kb and 100 kb
resolution observed matrices and then by dividing each
normalized score by the expected one extracted from
the KR expected file (as described previously in section
II.c of the Extended Experimental Procedures of refer-
ence [47]). KR expected values less than 1 were set to 1
to avoid long-distance interaction biases. HiC matrices
from Dixon et al. [48] were generated from the normal-
ized datasets at a 40 kb resolution and transformed to a
400 kb resolution by summing the contacts observed in
10 × 10 sub-matrices. Expected vectors represent the
mean number of contacts observed at a given distance
and were used to calculate the observed/expected
matrices.
Results
Clinical and molecular findings
Through physicians from a large network of medical
genetics centers, we enrolled a cohort of 149 individuals
presenting with a constellation of SMS features. High-
density 17p11.2 aCGH and Sanger sequencing of RAI1
showed that 134 out of 149 individuals presented a gen-
etic or genomic alteration of the RAI1 gene [9, 11, 17,
49–52], 96/134 (72 %) individuals carried the classic re-
current 3.7 Mb SMS deletion, ten (7.5 %) contained
an uncommon recurrent 1 (UR1) or UR2 rearrange-
ment, 24 (18 %) a non-recurrent RAI1 deletion, and
four (3 %) had a de novo variant in RAI1 [9, 11, 49,
52, 53] (Additional file 2 Table S1). Whereas these
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proportions are similar to published results [12, 54],
it is likely that some clinicians did not refer individ-
uals with SMS features who were negative for SMS
molecular diagnosis (via aCGH or fluorescence in situ
hybridization, FISH) or who were positive for another
potentially causative CNV, for example 1p36 deletion
syndrome [15, 55, 56] that shares multiple similarities
with SMS. Indeed, many individuals were molecularly
diagnosed prior to sample submission. Consistent
with this hypothesis, a separate study identified muta-
tions affecting RAI1 in only 30 % of participants with
a suspected diagnosis of SMS [12].
The remaining 15 individuals (10 %) showed no dis-
cernable perturbation of the RAI1 gene. The 13 with
available clinical data presented the following classical
SMS features: ID (12/12), DD (13/13), sleep disturbances
(8/10), and/or self-injurious behavior (10/11), in particu-
lar onychotillomania (6/7) (Additional file 1: Supplemen-
tary Text, Additional file 1: Table S1). To identify the
underlying cause of the phenotypes of these 15 individ-
uals, the probands and their parents when available (eight
cases) were subjected to high-resolution genome-wide
aCGH and whole-exome sequencing. We identified po-
tentially causative variants in ten individuals (Additional
file 2: Table S1). These were grouped into five categories:
(1) a 47, XYY karyotype (subject BAB2492); (2) de novo
variants in ZEB2 (BAB2386), CASK (BAB2540), KMT2D
(BAB2319), and JAKMIP1 (BAB2451); (3) compound het-
erozygote variants in GLDC (BAB4947); (4) a MECP2
variant in a woman with random X-inactivation
(BAB2552) inherited from the individual’s mother, who
presented with a skewed X-inactivation pattern (away
from this allele) in her blood (Additional file 3: Figure S5);
and (5) variants in POGZ (BAB2330, variant not mater-
nally inherited), MAP2K2 (BAB2474), and the X-linked
KDM5C (BAB2293), the origins of which could not be
assessed. We confirmed the segregation of sequence vari-
ants in available family members by Sanger sequencing.
Individual BAB2330 and four other carriers of heterozy-
gous truncating variants in POGZ allowed the recent de-
scription of a new syndromic form of intellectual disability
[57, 58]. We compared the phenotype of the remaining in-
dividuals (Additional file 1: Supplementary Text, Table 1,
Additional file 2: Table S1) with those associated with the
identified molecular diagnoses, including 47,XYY, Mowat-
Wilson syndrome (MOWS; OMIM#235730), mental
retardation and microcephaly with pontine and cerebellar
hypoplasia (MICPCH; OMIM#300749), Kabuki syndrome-
1 (KABUK1; OMIM#147920), glycine encephalopathy
(GCE; OMIM#605899), X-linked syndromic mental retard-
ation 13 (MRXS13; OMIM#300055), cardiofaciocutaneous
syndrome (CFC4; OMIM #615280), and X-linked syn-
dromic mental retardation Claes-Jensen type (MRXSC;
OMIM#300534) (Additional file 2: Table S4). While we
observed distinct clinical features in some individuals (e.g.
macrocephaly and seizures in the carriers of variants in
KDM5C and GLDC, respectively (Additional file 1: Supple-
mentary text)), features specific to SMS [59] are present in
a sufficient number of probands (Additional file 2: Table
S1). This allows us to hypothesize that in some cases the
molecular diagnosis hinted at potential underlying genetic
heterogeneity for SMS rather than misdiagnoses of other
syndromes, and that some of the 47,XYY, MOWS,
MICPCH, KABUK1, GCE, MRXS13, CFC4, and MRXSC
syndromes have a greater clinical phenotypic variability
than anticipated. This prompted investigation of the pre-
sumptive effect of the variants on the encoded proteins
and molecular perturbations that may underlie the ob-
served phenotypic manifestations (summarized in Table 1).
Variant analysis and modeling
The variants identified in KMT2D (p.E3418X) and
MECP2 (p.P389fsX) are predicted to be loss-of-function
alleles, which are likely pathogenic alleles as KMT2D
and MECP2 are “extremely intolerant” and “intolerant”
to loss-of-function variation according to the Exome
Aggregation Consortium database version 0.3 (http://
exac.broadinstitute.org) [10.2015] (pLI = 1.0 and 0.7,
respectively) and as analogous loss-of-function variants
in KMT2D and MECP2 were identified in KABUK1 [60]
and MRXS13 [61] individuals, respectively (Additional
file 2: Table S5 and S6). Additionally, the de novo variant
in the candidate gene JAKMIP1 (p.D586H) occurs in a
highly conserved residue and is predicted to be deleteri-
ous to the protein structure. JAKMIP1 is “extremely
intolerant” to loss-of-function variation according to
ExAC (pLI = 0.99). When possible, we used X-ray struc-
tures and/or cryo-EM modeling to obtain a 3D represen-
tation of the remaining encoded proteins and compared
the variants we identified with those previously reported
in MOWS, MICPCH, GCE, CFC4, and MRXSC individ-
uals (Additional file 2: Table S7–S11). By and large, these
models suggest that the variants identified in the current
study are detrimental to the encoded proteins: (1) the
ZEB2 p.H1049P variant substitutes a residue that partici-
pates in the coordination of the Zn++ atom of one of the
Zinc fingers, similar to the variant p.H1045R identified
in a MOWS individual (Additional file 3: Figure S6A;
Additional file 2: Table S11); (2) the MAP2K2 p.D69del
variant removes one of the two aspartic acid residues in-
volved in the binding of a Ca++ ion in the conserved
GELKDD loop (Additional file 3: Figure S6B); (3) the
GLDC p.L726Q and p.P647L variants likely affect the
packing of the encoded protein in the neighborhood of
the catalytic lysine K754 residue similar to the 61 mis-
sense variants identified in GCE individuals (Additional
file 3: Figure S6C, Additional file 2: Table S8); and (4)
the CASK p.R489W variant places a bulky tryptophan
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Table 1 Summary of clinical phenotypes of SMS patients without RAI1 alteration, variants assessment, and evidence of association with RAI1presented in this paper
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sidechain that cannot be accommodated in the structure
without changing the molecular surface (Additional file
3: Figure S6D). The possible impact of the KDM5C
p.K1023R variant on this conserved position (Additional
file 3: Figure S7) could not be evaluated as no template
is available for this region.
The identified rare variants affect Rai1-associated genes
We next proceeded to test the hypothesis that genes
mutated in individuals with SMS-like features were asso-
ciated with RAI1. To challenge this assumption, we first
assessed if HDAC4, MBD5, and PITX3, three genes pre-
viously reported to be associated with SMS phenotypes
[13, 14, 16], BRD2 and ZBTB17 (a.k.a. MIZ1), two genes
encoding high-confidence RAI1 interactors we identified
by two-hybrid assay (see “Methods”) and JAKMIP1,
ZEB2, CASK, KMT2D, GLDC, MECP2, MAP2K2,
POGZ, and KDM5C, the nine genes identified here, were
part of a RAI1 functional network. Manual curation of
the literature revealed single or double edges functional
relationships between 13 of these 15 genes, allowing a
maximum of two “extra” connecting nodes. This net-
work includes JAKMIP1, ZEB2, MECP2, and MAP2K2
(Fig. 1a; Table 1), indicating that may have uncovered a
“disease network” as previously described [62]. The sig-
nificance of the observed connectivity (P = 0.0167 was
assessed adapting spatial statistics concepts to network
analysis [31] (see “Methods”). Second, we used the
GIANT database (Genome-scale Integrated Analysis of
gene Networks in Tissues [63]) to assess whether these
14 genes form a functional network and eventually
capture tissue-specific functional interactions. When
considering GIANT data from neurons, CASK functions
as a provincial hub with nine edges and 12 genes
BA
Fig. 1 RAI1 Molecular interactions. a Literature-defined molecular interactions. Genes interactions network obtained combining literature text-
mining resources (i.e. PubMed, Google Scholar, iHOP, and EVEX) and visualized using Cytoscape. Nodes are colored depending on the role of the
gene: genes associated with SMS phenotypes in red (RAI1 is highlighted with a thicker outline); RAI1 interactors identified in yeast two-hybrid
screens in dark blue; genes with rare possibly damaging variants in SMS patients identified in this report in light blue; “extra nodes” required to
make connection are shown as white squares (maximum two “extra nodes” allowed), while “extra nodes” found in the 4C BRICKs of the RAI1 viewpoint
are depicted in green. b Co-expression-based molecular interactions. Tissue-specific functional interaction network built using GIANT (Genome-scale
Integrated Analysis of gene Networks in Tissues, http://giant.princeton.edu/) in “all tissues” (top panel) versus “neuron” (bottom panel), with minimum
relationship confidence = 0.5 and maximum number of genes = 15. RAI1, HDAC4, PITX3, MBD5, BRD2, MIZ1/ZBTB17, CASK, KMT2D, MECP2, GLDC, KDM5C,
MAP2K2, POGZ, and ZEB2 were used as queries
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(JAKMIP1, CASK, GLDC, HDAC4, KDM5C, KMT2D,
MAP2K2, MBD5, MECP2, RAI1, ZBTB17, and ZEB2) of
the 15 assessed are connected (p = 0.0439), further
supporting the notion of “disease network” as, in par-
ticular, HDAC4 and MBD5, two of the three genes previ-
ously associated with SMS-like phenotypes, are included
[13–15]. Eight out of 14 genes (BRD2, HDAC4, KDM5C,
MAP2K2, MECP2, POGZ, RAI1, and ZBTB17) including,
in particular, the two genes, BRD2 and ZBTB17, encoding
high-confidence RAI1 interactors, are functionally linked
in the “all tissue” network (p = 0.00814; Fig. 1b; Table 1;).
Furthermore, when RAI1 is used as single query gene,
RAI1 and CASK are directly linked in the resulting gene
network but, again, specifically in neurons (Additional file
3: Figure S8). These results and the data extracted from
the literature suggest that at least some of the eight genes
with variants potentially causing SMS-like phenotypes
could possibly be causative as they are functionally associ-
ated with RAI1.
To gain further insight about the genes regulated by
Rai1 during mouse embryonic development, we per-
formed microarray analysis on total RNA prepared from
three 10.5 dpc Rai1–/– embryos and from three of their
wild-type littermates. The two Rai1 transcripts present
on the array are significantly downregulated in Rai1–/–
embryos compared to wild-type littermates (e.g. the
AK013909 transcript with a fold change of 6.2 shows the
largest downregulation among the 45,037 assessed probe
sets). In fact, the expression values for both transcripts
are within background levels in the Rai1–/– embryos, in-
dicating that both transcripts are not expressed in the
Rai1–/– mutants and further corroborating the conten-
tion that the engineered Rai1 mutant allele is a complete
null allele [32]. In total, 142 and 157 probe sets showed
an over twofold increase or decrease, respectively
(Additional file 2: Table S12; see “Methods”) in the
mutant mice when compared to wild-type littermates.
Consistent with the hypothesis that genes potentially
causative of the SMS-like phenotypes are functionally
associated to or transcriptionally regulated by RAI1, the
expression levels of both Zeb2 (ENSMUSG00000026872)
and Map2k2 (ENSMUSG00000035027) were perturbed
in Rai1–/– mice (Additional file 2 Table S12). These ex-
pression arrays results were subsequently confirmed by
RT-PCR (Additional file 3: Figure S9). We then assessed
the chromosomal position of the dysregulated genes.
The enrichment score using a Pearson Chi-square good-
ness of fit statistic indicated that they showed a biased
chromosome distribution with 22 % of the genes down-
regulated and 26 % of the genes upregulated in the Rai1
mutants mapping to mouse chromosome 11 (MMU11)
where the Rai1 gene resides. Less than 5 % of the differ-
entially expressed genes are located on any chromosome
other than MMU11. This enrichment on MMU11 for
downregulated and upregulated genes in Rai1–/– em-
bryos is reminiscent of our previous finding that the
engineered MMU11 deletion and reciprocal duplication
that mimic SMS and Potocki-Lupski syndrome rear-
rangements were associated with a MMU11-wide tran-
scriptome perturbation in the five assessed adult male
tissues [64].
Chromatin architecture can similarly be exploited to
identify genes that belong to the same pathway. Long-
range chromatin contacts, which bring genes in close
proximity to regulatory sequences, have been shown to be
necessary for co-transcription of biologically related and
developmentally co-regulated genes [65, 66]. We recently
showed the pertinence of this approach by documenting
that genes associated with ASD and head circumference
phenotypes were linked by chromatin loops. As a third ap-
proach to assess if RAI1 is biologically related to the eight
genes identified in the SMS-like individuals, we used an
adapted version of the 4C method [35, 37, 67–69] to iden-
tify chromosomal regions that physically associate with
the RAI1 “viewpoint.” We independently analyzed the
local pattern of chromosomal interactions in LCLs of two
control individuals (Additional file 3: Figures S10, S3, and
S4, see “Methods”). Genome-wide, we detected 153 sig-
nificant BRICKs (FDR ≤ 1 %), i.e. 3D interacting genomic
fragments (see “Methods,” Additional file 2: Table S13),
encompassing 147 genes. Within the 66 (43 %) intrachro-
mosomal BRICKs, we identified, in particular, two gen-
omic intervals that flank the RAI1 viewpoint (Fig. 2a and
b) and which are de facto positive controls, as they were
previously reported to interact with RAI1 in high reso-
lution Hi-C (genome-wide conformation capture) from
LCLs [40, 47]. To further corroborate our 4C results we
validated selected interactions by 3C-PCR (Additional file
3: Figure S2). Although trans-DNA contacts from Hi-C
datasets are only reliable when determined over genomic
windows larger than single-restriction fragment [70], we
can report consistency between Hi-C results [40] and the
interchromosomal and intrachromosomal contacts we
identified in this report (Fig. 2c, Additional file 3: Figure
S11, Table 1, see “Methods”).
The genes mapping within the RAI1-chromatin con-
tacted genomic loci (BRICKs genes) are enriched for
genes that encode proteins that interact together (82 ob-
served interactions versus 35 expected; P = 6.41e–12).
BRICKs genes are also enriched for the GO term “detec-
tion of light stimulus involved in sensory perception” in
Enrichr (P = 5.45e–3) (see “Methods,” Additional file 2:
Table S14). Similarly, Enrichr showed that chromosome
contacts were enriched in interchromosomal and intra-
chromosomal cytobands (17p11, adjusted P < 1e–09;
17p12, adjusted P = 9.7e–09; 17p13, adjusted P = 1.8e–03;
and 2q22 adjusted P = 4.95e–02). ZEB2, one of the eight
genes found mutated in the SMS individuals, maps to
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the latter 2q22.3 region and is flanked by BRICKs. To
further assess possible functional relationships between
RAI1 and chromatin-contacted genes, we retrieved the
list of 322 genes flanking the BRICKs (BRICKs flanking
genes, i.e. the closest genes to be found upstream and
downstream of a BRICK within a 500 kb window). The
4C assays in particular identified interchromosomal con-
tacts with restriction fragments mapping 200 kb away
from the ZEB2 and GLDC gene loci. We then compared
the lists of BRICKs genes and BRICKs flanking genes
with the list of genes whose expression levels were per-
turbed in Rai1–/– mouse embryos. Although our analysis
is restricted by a small sample size, we found a consist-
ent trend of over-representation (Fisher’s enrichment
test, P = 0.22, OR = 1.5, and P = 0.2, OR = 1.4) with 10
and 18 chromatin-contacted BRICKs genes and BRICKs
flanking genes, respectively, differentially expressed in
the mouse knockdown model. Interestingly, 6/10 of
these BRICKs genes mapping at cytobands 17p13, 17p11
(2 genes), 17q21 and 17q23 (2 genes) have mouse ortho-
logs that map on mouse chromosome MMU11, thus
possibly explaining the enrichment of MMU11-mapping
genes within genes differentially expressed in Rai1–/–
mouse embryos (Additional file 3: Figure S12).
Discussion
Within a cohort of 149 individuals presenting clinical
features of SMS we identified 90 % (134/149) of
viewpoint
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Fig. 2 4C interactions profile of RAI1 and comparison with Hi-C interactions profiles locally and globally. a (Panels from top to bottom). Transcripts:
The structure of the transcripts mapping within human 17p11.2 cytoband from approximately 16.5 Mb to 18.5 Mb are indicated, in particular
those of the RAI1, TOM1L2, and ATPAF2 genes. Viewpoint: The red tick shows the mapping position of the RAI1 viewpoint used in the 4C experiments.
PC/BRICKs: Smoothed and profile-corrected 4C signal (upper part of each panel) and BRICKs (lower part) identified for each replicate (blue and burgundy).
The corresponding BRICKs significance heatmap color legend is shown in the bottom right corner. b High resolution Hi-C chromosome conformation
capture results obtained with the GM12878 LCL within the chromosome 17 17.25-18.22 Mb window (5 kb resolution). Yellow and light blue squares
highlight the contact domains and peaks identified in [47], respectively. The position of the RAI1, TOM1L2, and ATPAF2 genes is indicated. c Distribution
of Hi-C scores in selected (FDR1%) versus non-selected BRICKS (FDR10%). Virtual 4C-seq tracks were generated for the RAI1 viewpoint from
the GM12878 Hi-C results published in [47] (5 kb resolution) by extracting the Hi-C vectors from the KR normalized observed/expected
matrices. BRICKS found with the viewpoint were quantified by the mean Hi-C signals. The p value of the two-sided t-test is reported for
the comparison, together with the number of Hi-C bins and the % of non-NA bins
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individuals with either a heterozygous deletion of RAI1
or a predicted deleterious variant of the RAI1 gene. We
used recent advances in genome sequencing technolo-
gies to possibly identify genetic alteration(s) associated
with SMS in the remaining individuals. These strategies
were successfully applied to discover loci associated with
ID [71]. They revealed a large genic overlap between ID
and ASD, schizophrenia, and epileptic encephalopathy
[72], suggesting that some developmental disorders have
highly variable clinical presentations. They similarly
uncovered limitations to the phenotype-driven strat-
egy and conventional clinical paradigm of identifying
individuals with very similar presentations as they re-
vealed an unsuspected phenotypic variance of known
disorders [73, 74].
The diagnosis of SMS has primarily relied on clinical
suspicion and consideration in a differential diagnosis
followed by laboratory studies and confirmatory molecu-
lar findings. Since the individuals studied in this cohort
were ascertained by experienced clinicians, an aptitude
supported by the low number of individuals without a
RAI1 molecular diagnosis, we exploited the remaining
15 individuals to assess the possible heterogeneity of this
syndrome (Fig. 3). We identified potentially causal gen-
etic alterations in ten individuals. They comprise vari-
ants in the JAKMIP1, ZEB2, CASK, KMT2D, GLDC,
MECP2, MAP2K2, KDM5C, and POGZ genes, which are
associated with ASD, MOWS, MICPCH, KABUK1,
GCE, MRXS13, CFC4, MRXSC, and a new ID syndrome
[57], respectively, as well as a 47,XYY karyotype.
Fig. 3 Genetic heterogeneity, phenotypic variance, and misdiagnosis. a RAI1 and gene A are associated with Smith-Magenis syndrome (SMS) and
syndrome A, respectively, and variants (yellow “lightning bolts”) in those genes cause the green and blue phenotypes, respectively. b The pheno-
typic spectra of these diseases could be more variable than anticipated and result in overlapping features. Such overlap could be due to a
broader phenotypic variability of syndrome A, of SMS or of both syndromes (right panels). The rare variants in Rai1-associated genes identified in indi-
viduals with SMS-like features and reported here (red “lightning bolts”) could be explained by a combination of genetic heterogeneity of
SMS and allelic heterogeneity of gene A (c), an increased variance of syndrome A (d), or a misdiagnosis of SMS (e)
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Interestingly, although 8/15 individuals in this study
were male, two of the three mutations on the X chromo-
some were seen in female patients as opposed to the
male patients. Three of the men lack molecular diagno-
ses at this time, whereas only one woman lacks a cred-
ible candidate. Therefore, the over-representation of
women with mutations on the X chromosome may be
due to small sample size and a lack of recessive X-linked
mutations in the cohort or the presence of remaining
mutations of interest on the X.
It is important to the medical community to identify
phenotypic overlap between diseases, which suggests
common causes and alterations of the same pathways, as
this knowledge could be exploited therapeutically. In this
report, we identify previously unappreciated relation-
ships between SMS and its major driver RAI1 and other
diseases that include MOWS, MICPCH, KABUK1, GCE,
MRXS13, CFC4, and MRXSC. Literature mining, co-
expression data, transcriptome profiling of Rai1–/
–animal models, and chromosomal contacts support the
existence of a comprehensive “biological module” [75] or
“disease network” [62] underlying these diseases.
Although none of the 15 individuals described in this
study have traditional molecular diagnoses involving
RAI1 haploinsufficiency and thus should formally be
considered misdiagnoses, many have phenotypes with
considerable overlap with SMS (Fig. 3, Additional file 2:
Table S1, Additional file 1: Supplementary text).
BAB4947 presented facial dysmorphisms, SMS-like be-
havioral disturbances that include sleep problems, poly-
embolokoilamania, onychotillomania, brachycephaly,
and brachydactyly, as well as known GLDC-variants as-
sociated features such as seizures. His clinical diagnosis
could possibly be confounded by the likely presence of
two molecular diagnoses: compound heterozygous vari-
ants in GLDC and an inherited frameshift variant in
TCOF1, a gene associated with Treacher Collins
syndrome-1 (OMIM #154500) and possibly responsible
for the down-slanting eyes, everted lateral eyelids, and
malar hypoplasia. The clinical scenario is similar with
cases BAB2474 and BAB2540, who did not show CFC4-
(e.g. ectodermal anomalies, craniofacial features) and
MICPCH-distinctive features (e.g. microcephaly and
pontocerebellar hypoplasia). Likewise individual BA2492
has a constellation of symptoms (sleep disturbance, DD,
cognitive impairment, brachydactyly) compatible with
only the most severe 47,XYY sex chromosome aneu-
ploidy cases [76]. Consistent with the hypothesis of
expanded phenotypes, the phenotypic variability of
White-Sutton syndrome associated with variants in
POGZ keeps extending with clinical features including
ASD, DD, ID, schizophrenia, and microcephaly [57, 71,
77–83]. We can also not formally rule out that we have
not yet determined the true genetic cause(s) of the
phenotypic spectrum of these individuals or they occur
in presence of more complex, blended phenotypes as ex-
emplified by BAB4947 above. BAB2451 harbors a “prob-
ably pathogenic” variant (SIFT HumDiv score = 1;
HumVar score = 0.982) in the gene JAKMIP1. Recent
findings have linked the loss of JAKMIP1 to neuronal
translation dysregulation during synaptic development;
mice knocked out for the JAKMIP1 paralog display
social deficits, stereotyped activity, altered vocal commu-
nication, increased impulsivity, and other autistic-like
behaviors [84].
The presented results support the notion that at least
some of the identified variants in candidate SMS con-
tributory genes CASK, GLDC, KDM5C, KMT2D,
MAP2K2, MECP2, POGZ, and ZEB2 are causative of the
observed phenotypes and thus that modification of the
function of these genes is associated with a greater
phenotypic variability than previously expected (Fig. 3).
Conversely, one and two carriers of damaging RAI1 vari-
ants were identified within a total of 6381 ASD [79, 85]
and 2426 ID [71, 78, 86–89] individuals, respectively.
Whereas the phenotype of one of the ID individuals was
retrospectively found to be consistent with SMS [89], we
lack detailed phenotypic information regarding the other
two cases. If we assume that these two individuals do
not present with typical SMS features that would have
excluded them from these cohorts, it suggests that the
phenotype of carriers of RAI1 deleterious variants is
similarly more variable than anticipated.
Structural variations, especially large rearrangements
involving several genes, shape tissue transcriptomes and
impact the expression of genes mapping to their flanks
[64, 90]. We show that the homozygous deletion of Rai1
in mouse embryos [32] influences the expression of
several genes and in particular MMU11 genes. Further-
more, the RAI1 viewpoint contacts the orthologous
genes at the chromatin level. As some of these genes
contribute to phenotypes associated with RAI1 variation
(e.g. KRT17 with “hoarse voice” (HP:0001609), B9D1
with “low-set, posteriorly rotated ears” (HP:0000368),
“hypertelorism” (HP:0000316), and “microcornea”
(HP:0000482)), they could be involved in RAI1 pathways.
The relevance of using 3C-based approaches as unbiased
tools to discover clinically related genes is reinforced by
their successful application in assessing connected
regions involved in similar phenotypes [35] and genes
interacting with risk loci identified in genome-wide asso-
ciation studies (GWAS) [91, 92]. The contacted regions
encompass candidate genes involved in “detection of
light stimulus” and related gene ontology terms. These
processes all refer to photodetection, which controls
circadian rhythm and melatonin production from the
pineal gland. RAI1 is an important player in this mech-
anism, by controlling the transcriptional levels of
Loviglio et al. Genome Medicine  (2016) 8:105 Page 12 of 15
CLOCK, a key component of the mammalian circadian
oscillator that transcriptionally regulates many critical
circadian genes [93]. Another gene mapping within the
SMS critical region on chromosome 17p11.2 and linked
to these processes is the subunit 3 of the COP9 signal
transduction complex (COPS3), essential for the light
control of gene expression [94]. It is thus possible that
the disruption of the orthologous locus in the Rai1–/–
mice perturbs chromatin loops and affects expression
levels of RAI1-contacted/functionally associated genes.
We are well aware of the limitations of using LCLs in
this type of study, and particularly to assess chromatin
contacts between genes whose expression specificity
resides in other cell lineages. These experiments are
nevertheless worth pursuing simply because: (1) the pri-
mary human target tissues often remain beyond reach;
(2) we cannot exclude a broad to ubiquitous expression
pattern for the genes involved in these disease processes;
and (3) long range chromatin contacts were shown to be
stable across cell lines and tissues regardless of expres-
sion status [95]. Similar limitations apply to the use of
embryonic stem cell-derived material, while animal
tissues have a different set of shortcomings.
Conclusions
Our results strongly support a disease network associ-
ated with RAI1 and illustrate the utility of a comprehen-
sive multifaceted diagnostic approach even in the
presence of a distinctive disorder.
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